Differences in lipoprotein concentration and composition modify the plasma distribution of free and liposomal annamycin

Pharmaceutical Research

Volumn 13, Issue 3, 1996, Pages 462-468

  Wasan, Kishor M ^a,b   Morton, Richard E ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Annamycin; Dyslipidemia; Lipoproteins; Liposomes

Indexed keywords

ANNAMYCIN; ANTINEOPLASTIC AGENT; DOXORUBICIN; LIPID TRANSFER PROTEIN; LIPOPROTEIN; LIPOSOME;

ARTICLE; CANCER PATIENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG DISTRIBUTION; DYSLIPIDEMIA; FLUOROMETRY; HUMAN; LIPID BLOOD LEVEL; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; CARRIER PROTEINS; DOXORUBICIN; DRUG CARRIERS; HUMANS; LIPIDS; LIPOPROTEINS; LIPOSOMES;

EID: 0030001996     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016065114515     Document Type: Article

References (15)

1. R. Weiss, G. Sarosy, K. Clagett-Carr, M. Russo, and B. Leyland-Jones. Anthracycline analogs: the past, present, and future. Cancer Chemother. Pharmacol. 18:185-197 (1986).
2. L. Lanaz and J. A. Page. Cardiotoxicity of Adriamycin and related anthracyclines. Cancer Treat. Rev. 3:111-120 (1976).
3. H. M. Coley, P. R. Twentyman, and P. Workman. 9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance. Eur. J. Cancer. 6:665-667 (1990).
4. P Ahlgren, L. Panasci, J. Shelton, P. Gruner, D. Major, B. Leyland-Jones, S. Saletan, F. Pilkiewicz, and L. Haccoun. Phase II study of liposomal doxorubicin (TLCD99) in metastatic breast cancer. Proc ASCO 11:82-88 (1992).
5. A. Rahman, D. Carmichael, M. Harris, J. K. Roh. Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. Cancer Res. 46:2295-2300 (1986).
6. S. Oudard, A. Thierry, T. J. Jorgensen, and A. Rahman. Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes. Cancer Chemother. Pharmacol. 28:259-262 (1991).
7. R. Perez-Soler and W. Priebe. Anthracycline antibiotic with high liposome entrapment structural features and biological activity. Cancer Res. 50:4260-4266 (1990).
8. Y. Ling, W. Priebe, L. Y. Yang, T. G. Burke, Y. Pommier, and R. Perez-Soler. In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by Annamycin, an Anthracycline Derivative with High Affinity for Lipid Membranes. Cancer Res. 53:1583-1589 (1993).
9. Y. Zou, W. Priebe, Y. Ling, and R. Perez-Soler. Organ distribution and tumor uptake of annamycin a new anthracycline derivative with high affinity for lipid membranes, entrapped in multilamellar vesicles. Cancer Chemother. Pharmacol. 32:190-196 (1993).
10. K. M. Wasan, K. Vadiei, G. Lopez-Berestein, and D. R. Luke. Pharmacokinetics, tissue distribution and toxicity of free and liposomal amphotericin B in a diabetic rat model. J. Infect. Dis. 161:562-566 (1990).
11. K.M. Wasan, V. B. Grossie, Jr., and G. Lopez-Berestein. Concentrations in serum and distribution in tissue of free and liposomal amphotericin B in rats during continuous Intralipid Infusion. Antimicrobial Agents Chemother. 38:2224-2226 (1994).
12. K. M. Wasan, G. A. Brazeau, A. Keyhani, A. C. Hayman, and G. Lopez-Berestein. Role of liposome composition and temperature on the distribution of amphotericin B in serum lipoproteins. Antimicrob. Agents Chemother. 37:246-250 (1993).
13. K. M. Wasan, R. E. Morton, M. G. Rosenblum, and G. Lopez-Berestein. Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: Role of Lipid Transfer Protein. J. Pharm. Sci. 83:1006-1010 (1994).
14. G. L. Peterson. A simplication of the protein assay method of Lowery et al. which is more generally applicable. Anal. Biochem. 83:346-356 (1977).
15. M. Burstein, H. R. Scholnick, and R. Morfin. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J. Lipid Res. 11:583-595 (1970).